Individualization of Therapies for Patients with Advanced Differentiated Thyroid Cancers

摘要

Ithough describing experience related to but a single A patient, the manuscript by Crouzeix et al. (1) rep- resents an important counterpoint to the emphasis of most current therapeutic literature pertinent to radioiodine-re- fractory metastatic differentiated thyroid cancer (DTC). In particular, kinase inhibitors now understandably dom- inate present-day discussions related to DTC therapy, in large part owing to the attainment of dramatic clinical benefit in many DTC patients treated with agents in- cluding sorafenib (2, 3), sunitinib (4), or pazopanib (5). These recent innovations are clearly exciting and should not be minimized, but it is equally important to place them into the broader therapeutic context. The Crouzeix et al. (1) manuscript helps to do so in some respects; however, because it focuses ona single patient, other aspects of the broader therapeutic context are necessarily not addressed.